Results 131 to 140 of about 7,345,675 (294)

Stan's father Theopholis Cross [picture] /

open access: yes, 1900
Part of the Stan Cross Archive of cartoons and drawings, 1912-1974.; Inscription: "Stan's father Theopholis"--In ink, on verso.; Also available in an electronic version via the internet at: http://nla.gov.au/nla.pic ...
Cross, Stan, 1888-1977.
core  

Cross section and parametrization of charmonium decay

open access: yesPhysics Letters B
The parametrization forms of charmonium quasi two body decays are discussed in detail in this paper. The symmetry analysis and magnetic transition description are utilized to provide the multi-aspect comprehension of the decay dynamics, including the ...
Xiao-Hu Mo, Jin-Tao Chen, You-Kai Wang
doaj   +1 more source

APOBEC3 activity and DNA polymerase‐ε deficiency are associated with distinct IDH1 R132 hotspot mutations

open access: yesMolecular Oncology, EarlyView.
Isocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Kelly E. Butler   +3 more
wiley   +1 more source

Wally and the Major [picture] : cross purposes /

open access: yes, 1970
Part of the Stan Cross Archive of cartoons and drawings, 1912-1974.; Inscription: "Stan Cross 70/24"--In ink, lower right. "9205 Wed Jan 28. Cross Purposes"--In ink, right margin; "9205"--In pencil, upper right corner.; Also available in an electronic ...
Cross, Stan, 1888-1977.
core  

Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation

open access: yesMolecular Oncology, EarlyView.
Incomplete microwave ablation (iMWA) of liver cancer triggers a biphasic progression in residual tumors. At Day 3, the microenvironment is characterized by acute inflammatory responses and extracellular matrix (ECM) remodeling. By Day 14, a profound shift occurs toward oncogenic signal transduction and immunosuppression, marked by macrophage ...
Yu Liu   +9 more
wiley   +1 more source

Things that make Stan cross [picture] : what makes inflation? /

open access: yes, 1900
Part of the Stan Cross Archive of cartoons and drawings, 1912-1974.; Inscription: "Stan Cross"--In ink, lower right. "Page 5"--In ink, on note attached to verso.; Title devised by cataloguer.; Also available in an electronic version via the internet at ...
Cross, Stan, 1888-1977.
core  

Unique circulating miRNAome signatures captured with distinct molecular states in Lynch syndrome and sporadic colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Circulating microRNA profiles distinguish nonmalignant Lynch syndrome from cancer‐associated Lynch syndrome, sporadic colorectal cancer, and healthy controls. Age‐stratified analysis reveals disease‐specific regulatory states, and a six‐miRNA panel shows concordant separation in an independent colorectal tissue cohort.
Ramadhani Salum Chambuso   +5 more
wiley   +1 more source

Wally and the Major [picture] : cross purposes /

open access: yes, 1958
Part of the Stan Cross Archive of cartoons and drawings, 1912-1974.; Inscription: "Stan Cross 8/47"--Lower right. "5496 Mon Mar 10 Cross Purposes"--In ink, right margin; "5419"--In ink, upper right corner; "11"--In pencil, upper left corner.; Also ...
Cross, Stan, 1888-1977.
core  

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

open access: yesMolecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy